Raia Drogasil SA banner

Raia Drogasil SA
OTC:RADLY

Watchlist Manager
Raia Drogasil SA Logo
Raia Drogasil SA
OTC:RADLY
Watchlist
Price: 4.385 USD -4.09%
Market Cap: $7.5B

P/E

29.3
Current
20%
Cheaper
vs 3-y average of 36.6

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
29.3
=
Market Cap
$38.2B
/
Net Income
R$1.3B

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
29.3
=
Market Cap
$38.2B
/
Net Income
R$1.3B

Valuation Scenarios

Raia Drogasil SA is trading below its 3-year average

If P/E returns to its 3-Year Average (36.6), the stock would be worth $5.48 (25% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-68%
Maximum Upside
+39%
Average Downside
17%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple 29.3 $4.39
0%
3-Year Average 36.6 $5.48
+25%
5-Year Average 40.7 $6.09
+39%
Industry Average 9.5 $1.42
-68%
Country Average 9.9 $1.49
-66%

Forward P/E
Today’s price vs future net income

Today's Market Cap Net Income Forward P/E
$38.2B
/
Jan 2026
R$1.3B
=
29.3
Current
$38.2B
/
Dec 2026
R$1.8B
=
21.2
Forward
$38.2B
/
Dec 2027
R$2.3B
=
17
Forward
$38.2B
/
Dec 2028
R$2.7B
=
14.3
Forward
$38.2B
/
Dec 2029
R$3B
=
12.6
Forward

Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.

Market Distribution

Lower than 77% of companies in Brazil
Percentile
23nd
Based on 446 companies
23nd percentile
5.9
Low
0 — 7.3
Typical Range
7.3 — 13.5
High
13.5 —
Distribution Statistics
Brazil
Min 0
30th Percentile 7.3
Median 9.9
70th Percentile 13.5
Max 842.8

Raia Drogasil SA
Glance View

Market Cap
7.5B USD
Industry
Retail

Raia Drogasil SA, Brazil's pharmaceutical titan, stands as a testament to the transformative power of strategic mergers and innovative retail management. Born out of the merger of Drogasil and Droga Raia, two of Brazil's enduring pharmacy chains, the company today operates an extensive network of retail stores across the nation. This strategic merger in 2011 was not merely a consolidation of operations but a fusion of distinct corporate cultures and expertise, aimed at enhancing operational efficiencies and expanding market share. By leveraging economies of scale, Raia Drogasil has entrenched itself as a formidable force in Brazil's healthcare retail sector, boasting a strong presence in both high-density urban centers and emerging markets in Brazil. The company's business model is built on a robust mix of health and wellness products, encompassing everything from prescription medications to over-the-counter remedies and personal care items. Raia Drogasil has adeptly positioned itself to capitalize on Brazil's growing healthcare demands, thanks to its comprehensive product offerings and strategic store locations. Each store functions as both a destination for health-conscious consumers and a vital link in the greater logistical chain that ensures timely product availability. By intertwining brick-and-mortar retail with digital innovation, Raia Drogasil not only drives revenue through traditional sales channels but also through its dynamic e-commerce platform. This synergy allows the company to tap into the evolving preferences of tech-savvy consumers, thereby making Raia Drogasil a leader in seamlessly integrating shopping experiences that cater to modern customer expectations.

RADLY Intrinsic Value
3.869 USD
Overvaluation 12%
Intrinsic Value
Price $4.385
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett